Otto, Sven; Abu-Id, Mario Hakim; Fedele, Stefano; Warnke, Patrick H; Becker, Stephan T; Kolk, Andreas; Mücke, Thomas; Mast, Gerson; Köhnke, Robert; Volkmer, Elias; Haasters, Florian; Lieger, Olivier; Iizuka, Tateyuki; Porter, Stephen; Campisi, Giuseppina; Colella, Giuseppe; Ploder, Oliver; Neff, Andreas; Wiltfang, Jörg; Ehrenfeld, Michael; ... (2011). Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: Not just a sporadic coincidence - a multi-centre study. Journal of cranio-maxillo-facial surgery, 39(4), pp. 272-277. Oxford: Elsevier 10.1016/j.jcms.2010.05.009
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
1-s2.0-S1010518210001307-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (389kB) |
Bisphosphonates (BPs) are powerful drugs that inhibit bone metabolism. Adverse side effects are rare but potentially severe such as bisphosphonate-related osteonecrosis of the jaw (BRONJ). To date, research has primarily focused on the development and progression of BRONJ in cancer patients with bone metastasis, who have received high dosages of BPs intravenously. However, a potential dilemma may arise from a far larger cohort, namely the millions of osteoporosis patients on long-term oral BP therapy.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Craniomaxillofacial Surgery |
UniBE Contributor: |
Lieger, Olivier, Iizuka, Tateyuki |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1010-5182 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:08 |
Last Modified: |
05 Dec 2022 14:00 |
Publisher DOI: |
10.1016/j.jcms.2010.05.009 |
PubMed ID: |
20580566 |
Web of Science ID: |
000291459000010 |
BORIS DOI: |
10.7892/boris.443 |
URI: |
https://boris.unibe.ch/id/eprint/443 (FactScience: 199295) |
Actions (login required)
 |
Edit item |